Trial Profile

A randomized phase III trial of dexamethasone and aspirin (DA) versus dexamethasone, diethylstilbestrol and aspirin (DAS) in locally advanced or metastatic cancer of the prostate - immediate versus deferred diethylstilbestrol.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aspirin (Primary) ; Dexamethasone (Primary) ; Diethylstilbestrol (Primary) ; Ranitidine
Indications Prostate cancer
Focus Therapeutic Use

26 Jun 2013 Biomarkers information updated
24 Jun 2009 Additional lead trial centres (Orchid Cancer Appeal, Barts and The London Trust) and lead trial investigator (Shamash J) added as reported by UKCRN record.
24 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by UKCRN record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com